Share on Twitter Share Pinterest LinkedIn Email Share on Facebook Evidence is mounting that drugs used to treat depression and Alzheimer’s disease also can help patients recover from strokes.But there are conflicting findings from studies of these and other drugs given to recovering stroke patients. Large, well-designed studies are needed before any drug can be recommended routinely for stroke recovery, according to a study in the journal Drugs and Aging by neurologists Xabier Beristain, MD, and Esteban Golombievski, MD, of Loyola University Medical Center and Loyola University Chicago Stritch School of Medicine.“These medications have not yet been clearly proven to be of benefit to patients recovering from strokes,” Dr. Beristain said. Speech and physical therapies traditionally have been the mainstays of stroke rehabilitation programs. But more than half of stroke survivors are left with some neurological impairment. “The limitations of these rehabilitation efforts have sparked an interest in finding other ways to enhance neurological recovery,” Drs. Beristain and Golombievski write.So far, the most promising drug treatments are antidepressants to improve motor recovery and Alzheimer’s disease drugs to boost recovery from aphasia (impaired ability to speak, write and understand verbal and written language).About one in three stroke patients suffers depression, which can limit a patient’s ability to participate in rehabilitation. There is mounting evidence that the class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs (such as Prozac, Paxil and Celexa), may enhance neurological recovery beyond their effect on mood. Another type of antidepressant, norepinephrine reuptake inhibitor (NRI) also has shown benefit.An analysis of 56 clinical trials of SSRIs found the drugs appeared to improve dependence, disability, neurological impairment, anxiety and depression after stroke. However, these findings should be taken with caution because the studies have different designs. Several additional clinical trials now underway are evaluating the use of antidepressants to enhance stroke recovery.There is growing evidence that Alzheimer’s disease drugs called acetylcholinesterase inhibitors (including Aricept, Exelon and Razadyne) can improve aphasia in stroke patients. A second type of Alzheimer’s medication under study is memantine (Namenda). When used in combination with therapy, memantine has shown language benefits lasting at least one year when compared with a placebo. But clinical evidence of memantine for stroke recovery remains limited.So far, most studies of these and other drugs used for stroke recovery have been small, employing different methodologies and time windows between the stroke and the clinical intervention.“We need well-designed, large clinical trials with enough power to establish the usefulness of medications as adjuvants to rehabilitation before we can routinely recommend the use of these agents to enhance neurological recovery after stroke,” Drs. Beristain and Golombievski write.
FDA launches effectiveness study of healthcare antisepticsThe US Food and Drug Administration (FDA) today issued a proposed rule requesting additional scientific data to support the safety and effectiveness of certain ingredients used in over-the-counter healthcare antiseptics, the agency said in a news release.Healthcare antiseptics are primarily used in hospitals, clinics, outpatient settings, and long-term-care facilities. They include hand washes and rubs, surgical hand scrubs and rubs, and patient preoperative skin preparations, the FDA said. Their most common active ingredients are alcohol and iodines. The rule does not cover consumer antiseptics like antibacterial soaps and hand sanitizers.The rule will be published tomorrow in the Federal Register, and the FDA is allowing 180 days for public comment. The rule lists 25 antiseptics that the agency will assess, plus 3 combination products. The FDA recommends their continued use while researchers gather data.”Based on new scientific information and concerns expressed by outside scientific and medical experts on an FDA advisory committee, the agency is requesting additional scientific data to demonstrate that health care antiseptics in the over-the-counter drug monograph are generally recognized as safe and effective (GRASE) for their intended use to reduce bacteria that potentially can cause disease,” the agency said in the release.”The FDA’s request for more safety and effectiveness data for health care antiseptic active ingredients should not be taken to mean the FDA believes that these products are ineffective or unsafe.”The FDA last thoroughly assessed these products in 1994. The agency said emerging science suggests that for at least some healthcare antiseptic active ingredients, systemic exposure as shown by detection of antiseptic ingredients in the blood or urine is higher than previously thought, and existing data raise potential concerns about the effects of repeated daily exposure.The Association for Professionals in Infection Control and Epidemiology (APIC) and the Society for Healthcare Epidemiology of America (SHEA) today strongly supported the FDA’s actions. “Since all infection prevention and control guidelines are evidence-based, it is important to stay up-to-date on safety and effectiveness data to protect healthcare personnel and their patients,” the societies said in a joint statement.Apr 30 FDA news release Apr 30 FDA proposed rule Apr 30 APIC/SHEA statement NDM-1 in Dhaka water raises flag for rapid rise in drug-resistant bacteriaThe carbapenemase NDM-1, an enzyme that fosters the spread of extensively drug-resistant bacteria, has made its way very recently into a large portion of the environmental waters of Dhaka, Bangladesh, and is likely to continue its rapid spread, say the findings of a study published yesterday in Emerging Infectious Diseases.The authors, from Cardiff University in Wales, tested environmental water/sewage samples from 58 sites in seven regions of Dhaka in October 2012 for NDM-1 (New Delhi metallo-beta-lactamase variant 1) and found it was present in samples from 36 (62%) of the sites.They also found high rates of NDM-1 in gram-negative bacteria, particularly Escherichia coli, in gut samples. Gut carriage can lead to contamination of drinking water and food because of poor sewage treatment. In addition, since E coli causes common community-acquired infections that often require hospitalization, the likelihood of NDM-1–encoding E coli moving between the community and the hospital increases as gut carriage of the bacteria spreads.The authors say testing for NDM-1 in Dhaka water in 2008-09 did not detect its presence, nor did testing of gut samples in 2009-10, pointing to the rapidity with which it has spread. Apr 29 Emerg Infect Dis study Reports: 6 melioidosis cases in arid Australia, vaccine candidate progressBurkholderia pseudomallei, the agent that causes melioidosis, a disease of animals and humans that typically occurs in wet, tropical areas, can survive in harsh and even desert environments, as evidenced by an Emerging Infectious Diseases dispatch yesterday that detailed six human cases of the disease in the normally arid interior of Australia.The cases occurred over a 4-month period in 2011 after heavy rains and flooding in central Australia, which has a desert climate with low rainfall and often-dry riverbeds. None of the case-patients had traveled overseas or to the tropical part of the country, which lies in the north.All patients lived below the 20th latitude south; melioidosis historically occurs between latitudes 20 degrees south and 20 degrees north. Half the patients were male and half female; five were indigenous Aboriginal Australians.Three required intubation and ventilation for severe bacteremia. All received intravenous ceftazidime or meropenem followed by trimethoprim/sulfamethoxazole or a similar agent according to standard guidelines, and all survived. Multilocus sequence typing showed each of the isolates to be novel and unique, and none had any known single-locus variants.Outbreaks of meloidosis are not unheard of in the dry areas of Australia after flooding but have been rare. The authors say that “the geographic boundaries of B pseudomallei across the vast interior of the Australian continent and the extent of incursion into southern Australia remain entirely unclear,” that further study is needed, and that the diagnosis of meliodosis should be considered in the area, particularly after heavy rains and flooding.Apr 29 Emerg Infect Dis dispatchIn other melioidosis news, another report in Emerging Infectious Disease says consensus among a group of experts at a March 2014 meeting was reached on steps for advancing to the next stage of development of vaccines against B pseudomallei.To date, no standardized protocols have existed for the testing of candidate vaccines, meaning direct comparisons between them have not been possible, plus partial effectiveness has been demonstrated only in murine models.The meeting included members of the Steering Group on Melioidosis Vaccine Development (SGMVD), which was established in 2013, plus several additional experts from the United Kingdom and the United States.It was agreed that a gateway system similar to that used for tuberculosis vaccine candidates will be used. Head-to-head comparison of the candidate vaccines using standardized mouse models and a defined set of testing criteria will be carried out by an independent institute, after which vaccines to test in non-human primates will be selected.A melioidosis vaccine is “urgently needed,” for public health purposes, say the authors, but also for biodefense, in that B pseudomallei is categorized as an agent at high risk of “deliberate misuse as a weapon.”Apr 29 Emerg Infect Dis report
Covid-19 diagnoses in New Mexico. The bars show the number of new diagnoses versus day, and the line shows the seven-day average. Created by Eli Ben-Naim
Would you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletters To access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week.
The 15th annual Hamptons Happening to benefit the Samuel Waxman Cancer Research Foundation will take place on Saturday, July 13, from 6:30 to 10:30 PM at 900 Lumber Lane in Bridgehampton.Every year the benefit charms foodies with its array of dining options, and this year is no different. The new theme is “Tour de Cuisine,” providing guests with tastings from culinary destinations around the world. More than 350 guests are expected to attend.The honorees this year are Chef Honoree, Lidia Bastianich, founder of Honoring Generations of the Bastianich Family; Restauranteur Honoree, Ian Duke, owner of Southampton Social Club, Union Burger Bar, and Union Cantina; Fashion Honoree, desiger Nicole Miller; and Business Honoree, Antonella Bertello, owner of The Baker House 1650.“The proceeds generated by the Hamptons Happening help support more than 30 scientists who are some of the world’s brightest minds working diligently to develop a cure for cancer,” said Dr. Samuel Waxman, founder and CEO of the SWCRF.“The SWCRF seeks to award $1.6 million in new grants this year, and community support is critically important in this effort,” he continued. “We are always grateful and moved by the generosity of our honorees, sponsors, guests, and the more than 30 participating chefs, restaurants, wine and spirit makers, and food purveyors who make this fun summer event possible.”Hamptons Happening was one of the first charity events to offer tastings from both the South Fork of Long Island and bring in celebrated chefs from New York City. This year’s samples are by Attraversa, Backyard Brine, Baked by Melissa, The Baker House 1650, Becco, The Bristol, Candied Anchor, City Chefs Catering, Cutwater Spirits, Del Pesto, Felidia, Five Senses Catering, Haas Brothers, Harmless Harvest, Kurly Kurtosh, MarieBelle, Mercer’s, Otto, Owls Brew, Palm Bay International, Saaz, Simple Vodka, South Fork Bakery, Southampton Social Club, Super Coffee, Sydney’s “Taylor” Made, Splash, Union Burger Bar, and Union Cantina.The food might get guests to the tent, but it’s the research that fuels the passion.Since its humble beginnings in 1976, the Waxman Cancer Research Foundation has continued to uncover genetic and non-genetic changes that can cause cancer in the organs, in addition to blood-borne cancers like leukemia and lymphoma. The mission is clear: eradicate cancer through funding cutting-edge research. SWCRF has awarded more than $100 million to more than 200 researchers across the globe.Music this year will be provided by Pat Farrell and the Cold Spring Harbor Band (“The Billy Joel Tribute Show”), and DJ Jarrell Entertainment will offer up all-night dancing. “America’s Got Talent” finalist Caly Bevier, who was diagnosed with ovarian cancer at only 15 years old, will additionally give a special performance.The Hamptons Happening Event Chair is Marion Waxman. The event Co-Chair is Randi Schatz; Sponsorship Chair, Karen Amster-Young; Journal Chair, Erica Linden-Fineberg, and committee members include Chris Arlotta, Maria Fishel, Michelle Greenberg, Adi Heyman, Norah Lawlor, Jessica Mackin-Cipro, Laurie Schaffran, and Jessica Wasmuth. The event producer is Elissa Held. Individual tickets start at $425, with a $200 ticket for young professionals. For tickets, go to firstname.lastname@example.org Share
DeepOcean, a provider of services and technologies for the subsea industry, has hired Fugro for the provision of precise satellite positioning for the company’s entire fleet of vessels. The contract is valid for three years.Fugro will supply DeepOcean with three completely independent decimetre Global Navigation Satellite Systems.In addition, Fugro’s new Starfix.G2+ system, which has a 3D accuracy approaching that of GNSS RTK systems, and Fugro’s Starfix.G4 satellite correction service are part of the contract delivery.The DeepOcean fleet will be equipped with hardware and software developed by Fugro, providing independent positioning solutions on each vessel.
Deep Down, an oilfield services company, has received an order from the oil and gas company Shell for an umbilical and distribution system to support a production platform mooring line control system. Deep Down did not specify which production platform would be supplied under the contract.In addition to supporting platform positioning, the system will provide real time data collection during high seas and platform operations.The oilfield services company added that due to increasing safety standards for wave zone equipment, the system would be designed to survive extreme wave loading conditions and extended design life.Ron Smith, Chief Executive Officer of Deep Down, briefly commented: “This order represents another milestone in the relationship between Shell and Deep Down.”
Stay at the forefront of thought leadership with news and analysis from award-winning journalists. Enjoy company features, CEO interviews, architectural reviews, technical project know-how and the latest innovations.Limited access to building.co.ukBreaking industry news as it happensBreaking, daily and weekly e-newsletters Subscribe now for unlimited access To continue enjoying Building.co.uk, sign up for free guest accessExisting subscriber? LOGIN Subscribe to Building today and you will benefit from:Unlimited access to all stories including expert analysis and comment from industry leadersOur league tables, cost models and economics dataOur online archive of over 10,000 articlesBuilding magazine digital editionsBuilding magazine print editionsPrinted/digital supplementsSubscribe now for unlimited access.View our subscription options and join our community Get your free guest access SIGN UP TODAY
Subscribe to Building today and you will benefit from:Unlimited access to all stories including expert analysis and comment from industry leadersOur league tables, cost models and economics dataOur online archive of over 10,000 articlesBuilding magazine digital editionsBuilding magazine print editionsPrinted/digital supplementsSubscribe now for unlimited access.View our subscription options and join our community Get your free guest access SIGN UP TODAY To continue enjoying Building.co.uk, sign up for free guest accessExisting subscriber? LOGIN Subscribe now for unlimited access Stay at the forefront of thought leadership with news and analysis from award-winning journalists. Enjoy company features, CEO interviews, architectural reviews, technical project know-how and the latest innovations.Limited access to building.co.ukBreaking industry news as it happensBreaking, daily and weekly e-newsletters
ISRAEL: Plans to construct rail and light rail links to a military intelligence campus which is to be built at Likit near Be’er Sheva have been announced by Minister of Transport & Road Safety Miri Regev.The campus is expected to open in 2026, with thousands of people travelling to and from the site every day.The proposed rail links would provide a journey time of no more than 70 min from central Israel, and would also help to encourage people to live in the area as part of the government’s policy of encouraging development in the Negev region.Several transport options had been proposed, but the preferred choice would see a railway built between Likit and the existing network at Goral Junction, north of Be’er Sheva.A separate project using light rail or similar technology would connect the centre of Be’er Sheva with surrounding communities including Omer, Meitar and Lehavim, as well as the military facility.